Witkin JM - Search Results

1

In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu_2/3 receptor antagonist.

Witkin JM, Ornstein PL, Mitch CH, Li R, Smith SC, Heinz BA, Wang XS, Xiang C, Carter JH, Anderson WH, Li X, Broad LM, Pasqui F, Fitzjohn SM, Sanger HE, Smith JL, Catlow J, Swanson S, Monn JA. Witkin JM, et al. Neuropharmacology. 2017 Mar 15;115:100-114. doi: 10.1016/j.neuropharm.2015.12.021. Epub 2015 Dec 31. Neuropharmacology. 2017. PMID: 26748052

2

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG. Tzavara ET, et al. Among authors: witkin jm. Br J Pharmacol. 2003 Feb;138(4):544-53. doi: 10.1038/sj.bjp.0705100. Br J Pharmacol. 2003. PMID: 12598408 Free PMC article.

3

Enhancement of antidepressant potency by a potentiator of AMPA receptors.

Li X, Witkin JM, Need AB, Skolnick P. Li X, et al. Among authors: witkin jm. Cell Mol Neurobiol. 2003 Jun;23(3):419-30. doi: 10.1023/a:1023648923447. Cell Mol Neurobiol. 2003. PMID: 12825836

4

A rapid punishment procedure for detection of anxiolytic compounds in mice.

Witkin JM, Morrow D, Li X. Witkin JM, et al. Psychopharmacology (Berl). 2004 Feb;172(1):52-7. doi: 10.1007/s00213-003-1618-4. Epub 2003 Sep 18. Psychopharmacology (Berl). 2004. PMID: 14504684

5

Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying.

Li X, Morrow D, Witkin JM. Li X, et al. Among authors: witkin jm. Life Sci. 2006 Mar 20;78(17):1933-9. doi: 10.1016/j.lfs.2005.08.002. Epub 2005 Sep 22. Life Sci. 2006. PMID: 16182315

6

A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders.

Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. Witkin JM, et al. Trends Pharmacol Sci. 2005 Dec;26(12):609-17. doi: 10.1016/j.tips.2005.10.006. Epub 2005 Nov 2. Trends Pharmacol Sci. 2005. PMID: 16260047

7

In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.

Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. Alt A, et al. Among authors: witkin jm. Psychopharmacology (Berl). 2006 Apr;185(2):240-7. doi: 10.1007/s00213-005-0292-0. Epub 2006 Feb 10. Psychopharmacology (Berl). 2006. PMID: 16470401

8

Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice.

Li X, Need AB, Baez M, Witkin JM. Li X, et al. Among authors: witkin jm. J Pharmacol Exp Ther. 2006 Oct;319(1):254-9. doi: 10.1124/jpet.106.103143. Epub 2006 Jun 27. J Pharmacol Exp Ther. 2006. PMID: 16803860

9

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD. Rorick-Kehn LM, et al. Among authors: witkin jm. Psychopharmacology (Berl). 2007 Jul;193(1):121-36. doi: 10.1007/s00213-007-0758-3. Epub 2007 Mar 24. Psychopharmacology (Berl). 2007. PMID: 17384937

10

Anxiolytic-like effects through a GLUK5 kainate receptor mechanism.

Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE Jr, Witkin JM. Alt A, et al. Among authors: witkin jm. Neuropharmacology. 2007 Jun;52(7):1482-7. doi: 10.1016/j.neuropharm.2007.02.005. Epub 2007 Mar 2. Neuropharmacology. 2007. PMID: 17418283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page